Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Inhalation Sciences welcomes visiting scientist Jonah Dibbern from Kiel University

ISABPress release25.08.2026 klo 11.45

Huddinge, Sweden - Inhalation Sciences (ISAB) today announced the completion of a successful visiting research stay by Jonah Dibbern, a licensed pharmacist and PhD candidate at Kiel University, at its laboratories in Huddinge, Sweden.

Dibbern is currently pursuing his doctoral studies at Kiel University in the research group of Prof. Dr. Regina Scherließ, a recognized leader in the field of inhalation science. During his time as a visiting scientist at ISAB, Dibbern worked on joint inhalation research projects developed collaboratively between Kiel University and Inhalation Sciences.

Kiel University is widely regarded as one of the highest-ranking academic centers within the inhalation science community, and this visit marks another step in the ongoing collaboration between the two institutions.

During his visit, Dibbern used ISAB's PreciseInhale® platform to dose capsule-based interactive powder formulations and conducted release testing using the DissolvIt® system.

Commenting on the visit, Jonah Dibbern says:

"I received a very warm welcome from the ISAB team. My visit was enriched by valuable discussions, joint project ideas, and new scientific insights. We used the PreciseInhale® platform to dose capsule-based interactive powder formulations, and I was particularly impressed by its versatility and flexibility. The release testing performed with the DissolvIt® system was both smooth and insightful, thanks to the team's excellent support and a well-designed workflow."

"Although the analytical data have not yet been collected, I am nevertheless convinced that, irrespective of the results, my visit was a complete success."

Manoush Masarrat, CEO of Inhalation Sciences, comments further:

"We're delighted to have hosted Jonah at our labs in Huddinge. Visits like this reflect the strength of the relationship between our two organizations, and we're looking forward to continued joint work with Kiel University as we push inhalation science forward together."

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.